Revance Therapeutics Executive and Leadership Team

Nadeem Moiz, the Chief Executive Officer at Revance Therapeutics, directs the overarching corporate strategy and long-term vision for the biotechnology firm. Moiz oversees the development and commercialization of novel botulinum toxin products, ensuring alignment between clinical trial progress and market readiness. By coordinating with the Board and senior leadership, the Chief Executive Officer drives the organization toward achieving key milestones in aesthetic and therapeutic indications. This leadership role involves managing complex stakeholder relationships and securing the resources necessary for Phase III clinical trials. Nadeem Moiz maintains a focus on sustainable growth and innovation, positioning the company as a leader in the pharmaceutical sector. Through rigorous oversight of operational performance, the Chief Executive Officer ensures that the company meets its ambitious goals for product delivery and patient outcomes across North American markets.

Scott Leffler, the Chief Financial Officer at Revance Therapeutics, manages the financial health and capital allocation strategies of the organization. Leffler oversees budgeting, financial reporting, and investor relations, ensuring that the company maintains the necessary liquidity to fund ongoing Phase III clinical trials. By analyzing market trends and fiscal performance, the Chief Financial Officer provides the strategic insights required for long-term investment decisions. This role involves coordinating with the executive team to balance research expenditures with commercial growth objectives. Scott Leffler drives financial stability by implementing rigorous fiscal controls and optimizing capital structures to support the development of novel botulinum toxin products. Through careful management of financial resources, the Chief Financial Officer ensures that the company remains well-positioned to achieve its strategic goals, providing the necessary support for the firm's expansion into diverse therapeutic and aesthetic markets.

Nicholas Crowe, the Chief Operating Officer at Revance Therapeutics, manages the internal infrastructure and manufacturing processes required to scale production of botulinum toxin products. Crowe optimizes supply chain logistics and quality control systems to support the transition from clinical development to commercial distribution. Overseeing daily operations, the Chief Operating Officer ensures that manufacturing facilities adhere to strict regulatory standards while maintaining high efficiency. This role requires constant collaboration with research teams to streamline the path for DaxibotulinumtoxinA. Nicholas Crowe drives operational excellence by implementing scalable processes that support the company's expansion into new therapeutic markets. By monitoring production metrics and resource allocation, the Chief Operating Officer guarantees that the organization remains agile in a competitive biotechnology landscape, ultimately facilitating the successful delivery of advanced medical solutions to healthcare providers and patients.

Satish Kalala, the Chief Technology Officer at Revance Therapeutics, architects the digital and technical infrastructure supporting the company's research and development initiatives. Kalala directs the integration of advanced data analytics and laboratory information systems to accelerate the study of DaxibotulinumtoxinA. Overseeing the technological roadmap, the Chief Technology Officer ensures that the firm utilizes cutting-edge tools to enhance clinical trial accuracy and product formulation. This leadership role involves managing cybersecurity protocols and digital assets that protect proprietary biotechnology research. Satish Kalala drives innovation by aligning technical capabilities with the company's long-term goals for aesthetic and therapeutic product development. By fostering a culture of technical precision, the Chief Technology Officer supports the broader mission of delivering high-quality medical products, ensuring that the organization maintains a competitive edge through superior data management and technological infrastructure.

Matthew Argano, the Chief Human Resources Officer at Revance Therapeutics, directs the talent acquisition and organizational development strategies necessary to support a growing biotechnology workforce. Argano oversees recruitment, employee engagement, and performance management programs that align with the company's mission of medical innovation. By fostering a culture of excellence, the Chief Human Resources Officer ensures that the firm attracts and retains top-tier scientific and commercial talent. This role involves designing compensation structures and professional development pathways that motivate staff to achieve clinical and operational milestones. Matthew Argano drives organizational effectiveness by implementing policies that promote diversity, equity, and inclusion across all departments. Through the management of human capital, the Chief Human Resources Officer supports the company's ability to execute complex research projects and commercial strategies, ensuring that the workforce remains fully equipped to meet the demands of the evolving pharmaceutical industry.

Steven Kreider, the Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics at Revance Therapeutics, directs the commercialization strategies for the company's portfolio of botulinum toxin products. Kreider oversees sales operations, marketing initiatives, and market access programs designed to capture share in both aesthetic and therapeutic segments. By analyzing regional market dynamics, the Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics drives revenue growth through targeted outreach to healthcare providers and clinics. This role involves coordinating with clinical teams to ensure that product messaging aligns with the latest trial data. Steven Kreider manages the commercial launch strategy for new products, ensuring that the company effectively communicates the value of its medical solutions. Through the execution of robust sales strategies, the Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics secures the market position of the firm, driving long-term commercial success.

Kira Schwartz, the Chief Legal Officer at Revance Therapeutics, directs the legal and regulatory affairs that govern the company's biotechnology operations. Schwartz oversees intellectual property protection, contract negotiations, and compliance with pharmaceutical regulations across all clinical and commercial activities. By managing legal risks, the Chief Legal Officer ensures that the firm adheres to international standards while pursuing the development of novel botulinum toxin products. This role involves providing counsel on corporate governance and navigating the complex regulatory landscape associated with Phase III clinical trials. Kira Schwartz drives the protection of the company's proprietary assets, ensuring that all research and development efforts remain legally secure. Through the oversight of legal strategy, the Chief Legal Officer supports the organization's ability to operate effectively in a highly regulated environment, facilitating the safe and compliant delivery of medical innovations to the global market.